Chemistry:Claziprotamide
From HandWiki
Claziprotamide is an investigational new drug that is being evaluated for the treatment of rare metabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA). It acts as a positive allosteric modulator (PAM) of pantothenate kinases 1 and 3 (PANK1 and PANK2) which are critical for coenzyme A biosynthesis and cellular metabolism.[1][2]
References
- ↑ "Development of Brain Penetrant Pyridazine Pantothenate Kinase Activators". Journal of Medicinal Chemistry 67 (16): 14432–14442. August 2024. doi:10.1021/acs.jmedchem.4c01211. PMID 39136313.
- ↑ "Claziprotamide". PatSnap. https://synapse.patsnap.com/homepage/search?query_id=ec3f23d9-7b68-4fef-bc16-8da67b6fdbd5.
 |  |
